EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review

Hansa Mreyoud iD, Krysta Walter iD, Elizabeth Wilpula, Jeong M Park iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2928 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Hansa Mreyoud und 3 weiteren Autor:innen. Beteiligte Einrichtung: Michigan Medicine, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Organ Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium glucose co‐transporter 2 (SGLT2) inhibitors are used for the treatment of diabetes and for their cardiovascular and kidney benefits in patients with or without diabetes. Use in solid organ transplant recipients is controversial because transplant recipients were excluded from the major clinical trials assessing SGLT2 inhibitors. The goal of this review was to assess the available literature regarding the use of SGLT2 inhibitors in solid organ transplant recipients. A PubMed search was conducted for studies published in English through December 31, 2023. Studies were excluded if they were meta‐analyses, review articles, commentaries, single case reports, or in vitro studies, or did not involve the use of SGLT2 inhibitors in solid organ transplant recipients with a diabetic, cardiovascular, or kidney outcome being assessed. In the final review, 20 studies were included: kidney ( n = 15), heart ( n = 4), and liver/lung/kidney ( n = 1) transplant recipients. SGLT2 inhibitors had similar A1c reduction efficacy and were found to be weight neutral with possible weight reduction effects. Cardiovascular and kidney outcomes were not adequately assessed in the available studies. Adverse effects were reported to occur at a similar rate in transplant recipients compared to the general population. SGLT2 inhibitors were initiated ≥1‐year post‐transplant in most transplant recipients included in these studies. The overall safety and antihyperglycemic efficacy of SGLT2 inhibitors in kidney and heart transplant recipients is similar to the general population. Data assessing SGLT2 inhibitors use in solid organ transplant recipients for longer durations are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsOrgan TransplantationHumansTransplant RecipientsHypoglycemic AgentsDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

SGLT2diabetes mellitussolid organ transplanttransplant recipients

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Michigan Medicine, Ann Arbor, Michigan, USA.
  • College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Hansa Mreyoud, Krysta Walter, Jeong M Park

Zitieren

APA

Mreyoud, H., Walter, K., Wilpula, E., & Park, J. M. (2024). The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2928

Vancouver

Mreyoud H, Walter K, Wilpula E, Park JM. The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2928

BibTeX
@article{Mreyoud2024,
  author = {Mreyoud, Hansa and Walter, Krysta and Wilpula, Elizabeth and Park, Jeong M},
  title = {The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2928}
}
Kostenlos starten →